Sign in to view content

Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy

Scott D Walter, MD, MSc, FASRS

Video
Published 2021

Related

Long-term Anti-VEGF Treatment Following Vitrectomy for Endophthalmitis in Patients With Neovascular AMD
Zofia Anna Nawrocka (vel Michalewska), MD, PhD
Annual Meeting Talks
2018
Outcomes in Proliferative Diabetic Retinopathy Patients Lost to Follow-up After Panretinal Photocoagulation Versus Antivascular
Daniel Su, MD
Updates from the Field
2018
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more